Clinical Trial Detail

NCT ID NCT01754376
Title Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Massachusetts General Hospital
Indications

melanoma

Therapies

Aldesleukin + Vemurafenib

Age Groups: adult

Additional content available in CKB BOOST